A new study published in the Journal of Clinical Research by researchers at the University of Texas says they have developed a new vaccine that protects crab macaques from four haemorrhagic fever viruses, including the Ebola virus and Lassa virus, africa’s deadliest viruses.
Viral haemorrhagic fever is a natural epidemic disease caused by insect-borne virus, with hemorrhage and shock as the main clinical characteristics, no special treatment, the fatality rate is very high.
The researchers noted that the vaccine consists of a detoxifying rVSV vector that separates the Ebola virus, the Sudanese Ebola virus, the Marburg virus, and the laca virus glycoprotein.
Researchers from the University of Texas and the National Institutes of Health gave 20 crab macaques two times each. The macaques were then infected with four different haemorrhagic fever viruses and five blood draws were taken to check for their infection and immune response.
The results showed that serum IgG and neutralizing antibody reactions for all four glycoproteins were detected in all vaccinated macaques. A moderate and balanced cellularly induced immune response to viral glycoproteins has also been detected in most vaccinated macaques.
The unvaccinated macaques in the control group all became ill after contracting the virus, suggesting that vaccinations provided immunity to the disease.
Researchers say adding the non-galasha virus ingredient to the multi-price vaccine is an exciting development. They plan to conduct further vaccine tests on other Lassa strains to assess whether a single dose of the quadrat vaccine is safe and effective.